Literature DB >> 11578344

Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery.

G.M. Thomas1, A.J. Dembo, T. Myhr, B. Black, J.F. Pringle, G. Rawlings.   

Abstract

Between 1981 and 1991, 41 patients with carcinoma of the cervix recurrent only in the pelvis, or pelvis and para-aortic nodes after initial surgery, were treated with concurrent chemo-radiation (CT-RT). The total dose of radiation was tailored to the disease extent. Radiation was delivered to the pelvis and/or pelvis plus para-aortic nodes. Concurrent infusional 5-fluorouracil 1.5 g m-2 day-1 was delivered with bid radiation for one to three courses of 3 or 4 days. In addition, 10 patients received one or two courses of intravenous mitomycin C (Mit C) 6 mg m-2. Twenty-three of 40 evaluable (58%) had a complete response to CT-RT. Five have subsequently relapsed, two in pelvis alone, one in pelvis and distant sites and two with distant metastases only. Eighteen of 40 (45%) remain alive without disease from 3 to 113 months (median 57 months) after CT-RT. Sustained complete remissions and apparent cure have occured even in poor pronosis patients with pelvic side wall or common iliac nodal diease and those recurrent at short intervals from surgery. Using logistic regression the following varibles were examined for their prognostic significance for pelvic control and survival: Mit C, extent of pelvic diseases number of course of 5-FU, nodal status at original surgery and radiation dose. On multivariate analysis only the number of courses of 5-FU used was predictive of pelvic control and survival. Concurrent 5-FU and radiation is recommended as salvage therapy for patients wth recurrent locoregional cervical cancer.

Entities:  

Year:  1993        PMID: 11578344     DOI: 10.1046/j.1525-1438.1993.03040193.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.

Authors:  Sang-Won Kim; Mison Chun; Hee-Sug Ryu; Suk-Joon Chang; Tae Wook Kong; Eun Ju Lee; Yong Hee Lee; Young-Taek Oh
Journal:  Strahlenther Onkol       Date:  2017-03-29       Impact factor: 3.621

2.  Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women.

Authors:  Bandit Chumworathayi; Pissamai Yuenyao; Vorachai Tangvorapongchai; Sanguanchoke Luanratanakorn; Jeerichuda Pattamadilok; Srichai Krusun
Journal:  Radiat Med       Date:  2007-11-26

3.  Proton Therapy for Vaginal Reirradiation.

Authors:  Yun Rose Li; Maura Kirk; Lilie Lin
Journal:  Int J Part Ther       Date:  2016-12-30

4.  Resection of the vaginal vault for vaginal recurrence of cervical cancer after hysterectomy and brachytherapy.

Authors:  Akiko Abe; Maki Matoda; Sanshiro Okamoto; Eiji Kondo; Kazuyoshi Kato; Kohei Omatsu; Kenji Umayahara; Kuniko Utsugi; Nobuhiro Takeshima
Journal:  World J Surg Oncol       Date:  2015-04-02       Impact factor: 2.754

5.  Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).

Authors:  Nathalie Arians; Robert Foerster; Joachim Rom; Matthias Uhl; Falk Roeder; Jürgen Debus; Katja Lindel
Journal:  Radiat Oncol       Date:  2016-03-18       Impact factor: 3.481

6.  High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy.

Authors:  Yuka Kozai; Yoshiyuki Itoh; Mariko Kawamura; Rie Nakahara; Junji Ito; Tohru Okada; Fumitaka Kikkawa; Mitsuru Ikeda; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2019-08       Impact factor: 1.131

7.  Prognostic Effect of Primary Recurrence Patterns in Squamous Cervical Carcinoma After Radical Surgery.

Authors:  Zongkai Zhang; Long Jiang; Rui Bi; Xiaohua Wu; Guihao Ke; Jun Zhu
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

8.  SEOM guidelines for cervical cancer.

Authors:  A Oaknin; M J Rubio; A Redondo; A De Juan; J F Cueva Bañuelos; M Gil-Martin; E Ortega; A Garcia-Arias; A Gonzalez-Martin; I Bover
Journal:  Clin Transl Oncol       Date:  2015-12-09       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.